Wallace Advisory Group’s Verona Pharma VRNA Stock Holding History

Wallace Advisory Group’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,384	Closed	-$225K	–	173
2025 Q3	$225K	Buy	+2,384	New	+$249K	0.18%	150

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Wallace Advisory Group's VRNA Position: Q4 2025 in Review

Wallace Advisory Group sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 2,384 shares — an estimated $225K sold.

Wallace Advisory Group first reported a position in VRNA in Q3 2025 and held it in 1 quarter. The position peaked at $225K in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Wallace Advisory Group reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Wallace Advisory Group sold 2,384 Verona Pharma shares in Q4 2025, an estimated $225K.
Wallace Advisory Group first reported a position in Verona Pharma in Q3 2025 and held it in 1 quarter.
Wallace Advisory Group's Verona Pharma position peaked at $225K in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Wallace Advisory Group's 13F filing for Q4 2025, filed 23 Jan 2026.